Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

277.37 UNCHANGED
Streaming Delayed Price Updated: 4:15 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,249
Open 277.37
Bid (Size) 277.00 (1)
Ask (Size) 279.00 (1)
Prev. Close 277.37
Today's Range 277.37 - 277.37
52wk Range 211.71 - 329.72
Shares Outstanding N/A
Dividend Yield 3.07%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market
U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Ticking Time Bombs: 3 Dow Stocks to Dump While You Still Can
Uncover the vulnerabilities of these Dow stocks to sell, with potential declines due to cash flow issues, pricing pressures and flat sales. 
Via InvestorPlace
Topics Stocks
Exposures US Equities

Performance

YTD
-6.73%
-6.73%
1 Month
-2.00%
-2.00%
3 Month
-11.74%
-11.74%
6 Month
+6.34%
+6.34%
1 Year
+17.54%
+17.54%

More News

Read More
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
How Is The Market Feeling About Amgen?
Via Benzinga
Looking At Amgen's Recent Unusual Options Activity
Via Benzinga
Is Amgen Stock a Buy?
Via The Motley Fool
Moody’s, Booking, DraftKings, Amgen Stocks In Focus Ahead Of Earnings
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
What's Going On With CytomX Stock?
Via Benzinga
Sandoz Settles Patent Dispute With Amgen Related To Bone Disorder Drug Denosumab
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
Via Benzinga
Better Buy: Pfizer vs. Viking Therapeutics
Via The Motley Fool
1 No-Brainer Vanguard Fund to Buy Right Now
Via The Motley Fool
The Dividend Goldmine: 3 Shining Stocks With Growing Payouts
Via InvestorPlace
Amgen/AstraZeneca's Asthma Drug Tezspire Vs. Sanofi/Regeneron's Blockbuster Dupixent - Analyst Gives His Pick
Via Benzinga
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
Via InvestorPlace
Exposures Product Safety
Sell These 3 Blue-Chip Stocks Before the Next Earnings Stumble
Via InvestorPlace
Topics Stocks
Exposures US Equities
Can This High-Yield Dividend Stock Keep Beating the S&P 500?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Got $5,000? Here Are 3 Undervalued Stocks to Buy and Hold Forever
Via The Motley Fool
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
Via InvestorPlace
3 Stocks to Buy Low Today With High Hopes for Tomorrow
Via InvestorPlace
Amgen, Shell And More On CNBC's 'Final Trades'
Via Benzinga
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
Via InvestorPlace
3 High-Growth Biotech Stocks Investors Shouldn’t Sleep On in April
Via InvestorPlace
The 3 Most Undervalued S&P 500 Stocks to Buy in April 2024
Via InvestorPlace
Topics Economy Stocks
Exposures Economy US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.